Literature DB >> 20643383

Tourette syndrome: gene expression as a tool to discover drug targets.

Isaac H Liao1, Frank R Sharp.   

Abstract

Gene expression microarrays are a high-throughput, cost-effective method for measuring the expression of all genes in a sample. By comparing the expression patterns of healthy controls to diseased subjects, the genetic regulatory pathways underlying and affected by the disease can be elucidated. Furthermore, dysregulated genes are possible candidates for pharmaceutical therapy. Here, we consider the possibility of applying this approach to Tourette syndrome. We also review current theories of Tourette syndrome etiology and pharmacology. (c) 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20643383      PMCID: PMC5084234          DOI: 10.1016/j.nurt.2010.05.007

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  57 in total

1.  Lack of association between SLITRK1var321 and Tourette syndrome in a large family-based sample.

Authors:  J M Scharf; P Moorjani; J Fagerness; J V Platko; C Illmann; B Galloway; E Jenike; S E Stewart; D L Pauls
Journal:  Neurology       Date:  2008-04-15       Impact factor: 9.910

2.  A functional magnetic resonance imaging study of tic suppression in Tourette syndrome.

Authors:  B S Peterson; P Skudlarski; A W Anderson; H Zhang; J C Gatenby; C M Lacadie; J F Leckman; J C Gore
Journal:  Arch Gen Psychiatry       Date:  1998-04

3.  Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance.

Authors:  J T Walkup; M C LaBuda; H S Singer; J Brown; M A Riddle; O Hurko
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

4.  Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels.

Authors:  S Poliak; L Gollan; R Martinez; A Custer; S Einheber; J L Salzer; J S Trimmer; P Shrager; E Peles
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

5.  Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome.

Authors:  Gary R Gaffney; Paul J Perry; Brian C Lund; Kristine A Bever-Stille; Stephan Arndt; Samuel Kuperman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-03       Impact factor: 8.829

6.  Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls.

Authors:  J F Leckman; W K Goodman; G M Anderson; M A Riddle; P B Chappell; M T McSwiggan-Hardin; C J McDougle; L D Scahill; S I Ort; D L Pauls
Journal:  Neuropsychopharmacology       Date:  1995-02       Impact factor: 7.853

7.  A large Italian family with Gilles de la Tourette syndrome: clinical study and analysis of the SLITRK1 gene.

Authors:  Giovanni Fabbrini; Massimo Pasquini; Cinzia Aurilia; Isabella Berardelli; Guido Breedveld; Ben A Oostra; Vincenzo Bonifati; Alfredo Berardelli
Journal:  Mov Disord       Date:  2007-11-15       Impact factor: 10.338

8.  A twin study of Tourette syndrome.

Authors:  R A Price; K K Kidd; D J Cohen; D L Pauls; J F Leckman
Journal:  Arch Gen Psychiatry       Date:  1985-08

9.  Effects of atmospheric ozone on microarray data quality.

Authors:  Thomas L Fare; Ernest M Coffey; Hongyue Dai; Yudong D He; Deborah A Kessler; Kristopher A Kilian; John E Koch; Eric LeProust; Matthew J Marton; Michael R Meyer; Roland B Stoughton; George Y Tokiwa; Yanqun Wang
Journal:  Anal Chem       Date:  2003-09-01       Impact factor: 6.986

Review 10.  Neuroscience in the era of functional genomics and systems biology.

Authors:  Daniel H Geschwind; Genevieve Konopka
Journal:  Nature       Date:  2009-10-15       Impact factor: 49.962

View more
  2 in total

1.  Down-regulation of OPA1 in patients with primary open angle glaucoma.

Authors:  Thomas M Bosley; Ali Hellani; George L Spaeth; Jonathan Myers; L Jay Katz; Marlene R Moster; Barry Milcarek; Khaled K Abu-Amero
Journal:  Mol Vis       Date:  2011-04-27       Impact factor: 2.367

2.  The need for a proper definition of a "treatment refractoriness" in tourette syndrome.

Authors:  Mauro Porta; Marco Sassi; Claudia Menghetti; Domenico Servello
Journal:  Front Integr Neurosci       Date:  2011-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.